A randomised, controlled, assessor-blind, parallel groups, multicentre, multinational trial comparing the ovarian response after controlled ovarian stimulation with mixed protocols of follitropin delta (REKOVELLE) and highly purified human menopausal gonadotropin (MENOPUR) in women undergoing an assisted reproductive technology programme

Ferring Pharmaceuticals A/S0 个研究点目标入组 151 人开始时间: 2022年7月15日最近更新: 2024年7月22日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: Ferring Pharmaceuticals A/S
入组人数: 151

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 至 64（—）

入选标准

•Informed Consent Form signed prior to screening evaluations., In good physical and mental health as judged by the investigator, and willing and able to comply with the trial protocol., Pre-menopausal females between the ages of 18 and 40 years. The subjects must be at least 18 years (including the 18th birthday) when they sign the informed consent and no more than 40 years (up to the day before the 41st birthday) at the time of randomisation., Infertile women diagnosed with tubal infertility, unexplained infertility, endometriosis stage I/II or with partners diagnosed with male factor infertility, eligible for in vitro fertilisation (IVF) and/or intracytoplasmic sperm injection (ICSI) using fresh or frozen ejaculated sperm from male partner or sperm donor., Infertility for at least one year before randomisation for subjects =37 years or for at least 6 months for subjects =38 years (not applicable in case of tubal or severe male factor infertility)., Regular menstrual cycles of 21-35 days (both inclusive), presumed to be ovulatory., Transvaginal ultrasound documenting presence and adequate visualisation of both ovaries, without evidence of significant abnormality (e.g. no endometrioma greater than 3 cm, and no enlarged ovaries or ovarian cyst not due to polycystic ovarian syndrome, which would contraindicate the use of gonadotropins) and normal adnexa (e.g. no hydrosalpinx) within 1 year prior to randomisation. Both ovaries must be accessible for oocyte retrieval., Early follicular phase (cycle day 2-4) serum levels of FSH between 1 and 15 IU/L (results obtained within 3 months prior to randomisation).

排除标准

•Primary ovarian failure., Currently breast-feeding., Undiagnosed vaginal bleeding., Findings at the gynaecological examination at screening which preclude gonadotropin stimulation or are associated with a reduced chance of pregnancy, e.g. congenital uterine abnormalities or retained intrauterine device., Pregnancy (negative urinary pregnancy tests must be documented at screening and prior to randomisation) or contraindication to pregnancy.e exception of controlled thyroid function disease., Use of fertility modifiers during the last menstrual cycle before randomisation, including dehydroepiandrosterone (DHEA) or cycle programming with oral contraceptives, progestogen or estrogen preparations.ns., Hypersensitivity to any active ingredient or excipients in the medicinal products used in the trial., Previous participation in the trial., Use of any non-registered investigational drugs during the last 3 months prior to randomisation., Known endometriosis stage III-IV., Considered unsuitable for controlled ovarian stimulation with a dosing regimen corresponding to approximately 225 IU/day gonadotropin, as judged by the investigator., History of previous episode of OHSS or exuberant ovarian response to gonadotropins, and polycystic ovarian syndrome.egnancy., One or more follicles =10 mm (including cysts) observed on the transvaginal ultrasound prior to randomisation on stimulation day 1 (puncture of cysts is allowed prior to randomisation)., Any known endocrine or metabolic abnormalities (pituitary, adrenal, pancreas, liver or kidney) which can compromise participation in the trial with the exception of controlled thyroid function disease., Known tumours of the ovary, breast, uterus, adrenal gland, pituitary or hypothalamus which would contraindicate the use of gonadotropins., Fibroid tumours of the uterus incompatible with pregnancy., Active arterial or venous thromboembolism.

研究者

发起方

Ferring Pharmaceuticals A/S

相似试验

进行中（未招募）

1 期

EUCTR2013-001669-17-PLFerring Pharmaceuticals A/S1,350

进行中（未招募）

不适用

A randomised, controlled, assessor-blind, parallel groups, multinational,multicentre trial assessing the dose-response relationship of FE 999049in controlled ovarian stimulation in women undergoing an assistedreproductive technology programmeMedDRA version: 14.0Level: PTClassification code 10021926Term: InfertilitySystem Organ Class: 10038604 - Reproductive system and breast disordersInfertility

EUCTR2011-000633-36-DKFerring Pharmaceuticals A/S330

进行中（未招募）

1 期

A randomised, controlled, assessor-blind, parallel groups, multicentre, multinational trial comparing the efficacy and safety of FE 999049 with follitropin alfa (GONAL-F) in controlled ovarian stimulation in women undergoing an assisted reproductive technology programmeMedDRA version: 14.1Level: PTClassification code 10021926Term: InfertilitySystem Organ Class: 10038604 - Reproductive system and breast disordersInfertility

EUCTR2013-001669-17-ESFerring Pharmaceuticals A/S1,350

进行中（未招募）

1 期

EUCTR2013-001669-17-GBFerring Pharmaceuticals A/S1,350

招募中

1 期

A trial to compare the ovarian response of REKOVELLE and GONAL-F in conventional dosing in women undergoing controlled ovarian stimulatioInfertility in women undergoing assisted reproductive technologies (ART) such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycleMedDRA version: 20.0Level: PTClassification code 10021928Term: Infertility femaleSystem Organ Class: 10038604 - Reproductive system and breast disorders

EUCTR2021-001785-38-ATFerring Pharmaceuticals A/S300